Canaccord Genuity Believes Maximus (NYSE: MMS) Still Has Room to Grow

By Ryan Adsit

In a report released yesterday, Richard Close from Canaccord Genuity maintained a Buy rating on Maximus (NYSE: MMS). The company’s shares closed yesterday at $71.67, close to its 52-week high of $72.29.

Close commented:

“We expect this to be a topic at JP Morgan. We also expect provider organizations to discuss specific strategies for improving productivity and driving ROI from previous large investments (i.e., EHR and RCM systems) in recent years. This would be relevant to companies including PINC, HSTM, in addition to the core HCIT companies mentioned above.”

According to TipRanks.com, Close is a 4-star analyst with an average return of 8.4% and a 54.2% success rate. Close covers the Services sector, focusing on stocks such as Patterson Companies Inc, Team Health Holdings, and Envision Healthcare.

Maximus has an analyst consensus of Hold, with a price target consensus of $65.33.

Maximus’ market cap is currently $4.67B and has a P/E ratio of 22.54. The company has a book value ratio of 4.9659.

Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MAXIMUS, Inc. engages in the management of government health and human services programs. It operates through the following segments: Health Services, U.S. Federal Services, and Human Services.